The relationship between the antitumor activity and the ribonucleotide reductase inhibitory activity of (E)-2'-deoxy-2'-(fluoromethylene) cytidine, MDL 101,731

Anti-Cancer Drugs

Volumn 9, Issue 7, 1998, Pages 653-657

  Kanazawa, Junji ^a   Takahashi, Takeshi ^a   Akinaga, Shiro ^a   Tamaoki, Tatsuya ^a   Okabe, Masami ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Antitumor effect; Deoxycytidine analog; Lung carcinoma; MDL 101,731; Mechanism of action; Ribonucleotide reductase

Indexed keywords

2' DEOXY 2' METHYLENECYTIDINE; CYTARABINE; CYTIDINE DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; TEZACITABINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MALE; MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; RIBONUCLEOTIDE REDUCTASES; TUMOR CELLS, CULTURED;

EID: 0031656656     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199808000-00011     Document Type: Article

References (27)

1. Elford HL, Freese M, Passamani F, Morris HP. Ribonucleotide reductase and cell proliferation. J Biol Chem 1970; 245: 5228-33.
2. Saeki T, Takahashi T, Okabe M, et al. Immunohistochemical detection of ribonucleotide reductase in human breast tumors. Int J Oncol 1995; 6: 523-9.
3. Elford HL, Effect of hydroxyurca on ribonucleotide reductase. Biochem Biophys Res Commun 1968; 33: 129-35.
4. Heineman V, Xu Y-Z, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38: 567-72.
5. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19: 11-9.
6. Francis AA, Blevins RD, Carrier WL, Smith DP, Regan JD. Inhibition of DNA repair in ultraviolet-irradiated human cell by hydroxyurea. Biochem Biophys Acta 1979; 563: 385-92.
7. Huang P, Chubb S, Hertel LW, Grindley GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
8. Boven E, Schipper II, Erkelens CA, Hatty SA, Pinedo HM. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993; 68: 52-6
9. Braakhuis BJ, van Dongen GA, Vermorken JB, Snow GB. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 1991; 51: 211-4.
10. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-22.
11. Martin C, Lund B, Anderson II, Thatcher N. Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Res 1996; 7: 351-7.
12. Noble S, Goa KL, Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997, 54: 447-72.
13. Gandhi V, Huang P, Xu Y-X, Heinemann V, Plunkett W. Metabolism and action of 2′,2′-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol 1991; 309A: 125-30.
14. Bitonti AJ, Dumont JA, Bush TL, et al. Regression of human breast tumor xenografts in response to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 1994; 54: 1485-90.
15. Bitonti AJ, Bush TL, Lewis MT, Sunkara PS. Response of human colon and prostate tumor xenografts to (E)-2′-deoxy-2′-(fluoromethylene) cytidine, an inhibitor of ribonucleoside reductase. Anticancer Res 1995; 15: 1179-82.
16. Kanazawa J, Takahashi T, Gomi K, Okabe M. Antitumor activity of (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleotide reductase. Proc Am Ass Cancer Res 1995; 36: 405.
17. Piepmeier JM, Rabidou N, Schold CS, Bitonti AJ, Prakash NJ. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL 101,731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res 1996; 56: 359-61.
18. Yamagami K, Fujii A, Arita M, et al. Antitumor activity of 2′-deoxy-2′-methylidenecytidine, a new 2′-deoxycytidine derivative. Cancer Res 1991; 51: 2319-23.
19. Takahashi T, Nakashima A, Kanazawa J, et al. Metabolism and ribonucleotide reductase inhibition of (E2)-2′-deoxy-2′-(fluoromethylene)cytidine, MDL 101,731 in human cervical carcinoma HeLa S3 cells. Cancer Chemother Pharmacol 1998; 41: 268-74.
20. Baker CH, Banzon J, Stubbe J, et al. 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorcytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chein 1991; 34: 1879-84.
21. Cory AH, Samano V, Robins MJ, Cory JG. 2′-Deoxy-2′-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture. Biochem Pharmacol 1994; 47: 365-71.
22. Tashiro T, Inaba M, Kobayashi T, et al. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemo ther Pharmacol 1989; 24: 187-92.
23. Cohen EA, Charron J, Perret J, Langelier Y. Herpes simplex virus ribonucleotide reductase induced in infected BHK-21/C13 cells: biochemical evidence for the existence of two non-identical subunits, H1 and H2. J Gen Virol 1985; 66: 733-45.
24. McCarthy JR, Matthews DP, Stemerick DM, et al. Stereospecific method to E and Z terminal fluoro olefins and its application to the synthesis of 2′-deoxy-2′-fluoromethylene nucleosides as potential inhibitors of ribonucleoside diphosphate reductase. J Am Chem Soc 1991; 113: 7439-40.
25. Yonetani Y, Mizukami T. Kinetic analysis of inhibition of human ribonucleotide reductase and DNA polymerase a by a new anticancer agent, (E)-2′-deoxy-2'′-(fluoromethylene)cytidine. Proc Am Ass Cancer Res 1996; 37: 405.
26. Townsend AJ, Cheng YC. Sequence-specific effects of ara-5-aza-CTP and ara-CTP on DNA synthesis by purified human DNA polymerases in intro: visualization of chain elongation on a defined template. Mol Pharmacol 1987; 32: 330-9.
27. Matsuda A, Azuma A, Nakajima Y, et al. Design of new types of antitumor nucleosides: the synthesis and antitumor activity of 2′-deoxy-2′-C-substituted) cytidines. In: Chu CK, Baker DC, eds. Nucleosides and nucleotides as antitumor and antiviral agents. New York: Plenum Press 1993: 1-22.